Skip to main content

Table 1 Patients in high-risk subgroup categories (CE population)

From: Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

CAP

HAP (excluding VAP)

Baseline risk factor

Ceftobiprole

Ceftriaxone ± linezolid

Baseline risk factor

Ceftobiprole

Ceftazidime plus linezolid

Any risk factor

193

205

Any risk factor

169

138

PORT ≥ III

126

117

APACHE score ≥ 15

67

59

PORT ≥ IV

51

58

>10 comorbidities

63

61

Sepsis

123

135

Mechanical ventilationa

38

37

Bacteraemiab

7

14

Bacteraemiab

15

11

Age ≥ 75 years

39

50

Age ≥ 75 years

59

54

COPD

51

59

COPD

55

39

ICU

25

26

ICU

73

59

  1. aMechanical ventilation at baseline or at any point during the study
  2. bFurther analyses were not conducted in the bacteraemia group as the number of patients in both treatment arms was below 20
  3. APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired pneumonia, CE clinically evaluable, COPD chronic obstructive pulmonary disease, HAP hospital-acquired pneumonia, ICU intensive care unit, PORT Patient Outcome Research Team, VAP ventilator-associated pneumonia
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us